Utilisation of transdermal fentanyl in Germany from 2004-2006 by Edeltraut Garbe and colleagues

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 8, 2012, Pages 902-903

  Sabatowski, Rainer ^a   Scharnagel, Rüdiger ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; LEVOMETHADONE; MORPHINE; NALOXONE; OXYCODONE; PETHIDINE; PIRITRAMIDE; TRAMADOL;

CANCER DIAGNOSIS; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; DROWSINESS; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENCY; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DRUG WITHDRAWAL; GERMANY; HUMAN; LETTER; LOW DRUG DOSE; MEDICAL SOCIETY; NAUSEA; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); VOMITING; WORLD HEALTH ORGANIZATION;

ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; PAIN;

EID: 84864374986     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3315     Document Type: Letter

References (14)

1. Garbe E, Jobski K, Schmid U. Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 2012; 21: 191-198.
2. Arzneimittelkommission der Deutschen Ärzteschaft. Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen. Deutsches Ärzteblatt 2012; 109: B628-629.
3. Cepeda MS, Fife D, Chow W, Matrogiovanni G, Henderson SC. Opioid Shopping Behavior: How Often, How Soon, Which Drugs, and What Payment Method. J Clin Pharmacol [Epub 1 February 2012]. DOI: 10.1177/0091270012436561.
4. Cepeda MS, Etropolski M, Weinstein R, Fife D, Boston R, Matcho A. Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States. BMC Palliat Care 2010; 9: 14.
5. Mercadante S, Porzio G, Ferrera P, et al. Low doses of transdermal buprenorphine in opioid-naïve patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009; 31: 2134-2138.
6. Vielvoye-Kerkmeer APE, Mattern C, Uitendaal MP. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronik cancer pain in opioid-naive patients and a group using codein. J Pain Symptom Manage 2000; 19: 185-192.
7. Klepstad P, Kaasa S, Borchgrevink PC. Starting Step III opioids for moderate to severe pain in cancer patients: Dose titration: A systematic review. Palliat Med 2011; 25: 424-430.
8. Heads of Medicines Agencies. Fentanyl Transdermal Patch SPC. (accessed 18 April 2012).
9. Janssen-Cilag. Durogesic SMAT: Fachinformation. Janssen-Cilag: Beerse, 2011.
10. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med 2011; 25: 402-409.
11. Schwabe U, Paffrath D (ed.). Arzneiverordnungs-Report 2011. Springer Verlag: Stuttgart, 2012.
12. Pflughaupt M, Scharnagel R, Gossrau G, Kaiser U, Koch T, Sabatowski R. Physicians' knowledge and attitudes concerning the use of opioids in the treatment of chronic cancer and non-cancer pain. Schmerz 2010; 24: 267-275.
13. Reinecke H, Sorgatz H. S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz 2009; 23: 440-447.
14. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Langzeitanwendung von Opioiden bei nicht-tumorbedingten Schmerzen (LONTS). (accessed 18 April 2012).